Welcome to our dedicated page for BIOSTEM TECHNOLOGIES NEW news (Ticker: BSEM), a resource for investors and traders seeking the latest updates and insights on BIOSTEM TECHNOLOGIES NEW stock.
BioStem Technologies is a leading innovator in regenerative therapies, utilizing perinatal tissue to develop and commercialize allografts that change lives. Their proprietary BioREtain® processing method preserves tissue structure and growth factors, setting them apart in the market. With quality brands like AmnioWrap2™ and VENDAJE®, BioStem Technologies is at the forefront of regenerative medicine.
News
Rhea-AI Summary
BioStem Technologies Inc. plans to release its third quarter 2023 financial results on Tuesday, November 14, 2023. The company will host a conference call and webcast to discuss the financial results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
-
Rhea-AI Summary
BioStem Technologies Inc. has closed an oversubscribed private placement of common stock, raising $2 million in gross proceeds. The placement consisted of 1,337,000 units at a price of $1.50 per unit. The company plans to use the net proceeds to complete clinical trials, expand brand awareness and product distribution, and execute product pipeline plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
-
Rhea-AI Summary
BioStem Technologies Inc. has announced the opening of the first site for its clinical trial evaluating the Vendaje tissue allograft in the treatment of diabetic foot ulcers. The trial aims to showcase the effectiveness of the product and the advantages of BioStem's proprietary BioREtain process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.7%
Tags
News
Rhea-AI Summary
BioStem Technologies Inc. to showcase its Vendaje® and AmnioWrap2TM portfolios at the 2023 Symposium on Advanced Wound Care Fall Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
-
Rhea-AI Summary
BioStem Technologies hails the withdrawal of final local coverage determinations for cellular and/or tissue-based products for DFU and VLU, which positively impacts patient treatment options. This is an important milestone for BioStem as they work towards delivering cutting-edge wound care management products and addressing a significant market opportunity, adding long-term value for shareholders. BioStem also received IRB approval for a clinical study on the utilization and effects of their VendajeⓇ wound care products in DFU.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
-
News
Rhea-AI Summary
BioStem Technologies Inc. has announced the approval of an IRB-sanctioned clinical study to investigate the utilization and effects of Vendaje in diabetic patients with foot ulcers. This study aims to enhance scientific understanding and improve care for people at risk of amputation. Diabetic foot ulcers are a significant risk, with approximately 15% of people with diabetes developing them. Vendaje is a placental-derived tissue allograft that provides mechanical protection and functional support for cell attachment, aiding the body's natural healing cascade.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.09%
Tags
Rhea-AI Summary
BioStem Technologies Inc. partners with Venture Medical for the nationwide release of AmnioWrap2, a versatile biologic skin substitute for wound care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
-
Rhea-AI Summary
BioStem Technologies Inc. engages PCG Advisory as advisor for investor relations and strategic communications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29%
Tags
-
Rhea-AI Summary
NovaBay Pharmaceuticals launches Avenova Allograft in the US eyecare market, expected to compete in the $403.6 million ophthalmology amniotic membrane market. The product launch follows a previously announced agreement with BioStem Technologies. NovaBay's physician-dispensed channel continues to grow, providing a strong platform for the innovative product. Avenova Allograft is available in multiple sizes and aims to improve ocular surface health. NovaBay also offers a suite of other eyecare products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
Rhea-AI Summary
NovaBay Pharmaceuticals and BioStem Technologies announce agreement for commercialization of Amniotic Tissue Allograft
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.86%
Tags
FAQ
What is the current stock price of BIOSTEM TECHNOLOGIES NEW (BSEM)?
The current stock price of BIOSTEM TECHNOLOGIES NEW (BSEM) is $13.1 as of October 15, 2024.
What is the market cap of BIOSTEM TECHNOLOGIES NEW (BSEM)?
The market cap of BIOSTEM TECHNOLOGIES NEW (BSEM) is approximately 234.2M.
What sets BioStem Technologies apart from competitors?
BioStem Technologies differentiates itself with the proprietary BioREtain® processing method that preserves tissue structure and growth factors, ensuring effective regenerative therapies.
What products does BioStem Technologies offer?
BioStem Technologies' portfolio includes quality brands like AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®, all aimed at providing cutting-edge regenerative solutions.
Where are BioStem Technologies' products processed?
All BioStem Technologies placental allografts are processed at the FDA-registered and AATB-accredited site in Pompano Beach, Florida, ensuring quality and safety.
How does BioStem Technologies contribute to the wound care market?
BioStem Technologies plays a significant role in the wound care market by leveraging natural properties of perinatal tissue to develop allografts that support wound healing and tissue regeneration.
What is the significance of BioStem Technologies' recent patent approval?
BioStem Technologies' patent approval for their method of processing human amniotic tissue strengthens their intellectual property and positions them as a leader in regenerative medicine.
BIOSTEM TECHNOLOGIES NEW